Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Rapacuronium bromide (Raplon) is a neuromuscular blocking agent administered by injection for use during anesthesia. It is a rapid-onset, short-acting paralytic agent used to facilitate endotracheal intubation and provide muscle relaxation during surgical procedures.
As LOE approaches, the brand team is likely contracting; positions focus on managed transition and defending remaining market share against generics.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Raplon at this stage offers limited career growth as the product approaches loss of exclusivity with zero linked job openings. Roles are primarily defensive, focused on protecting remaining market share and managing the transition to generics rather than driving innovation.
Worked on RAPLON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.